

28TH ACSB MEETING SUMMARY REPORT

AGENDA ITEM	TOPIC	DISCUSSION	DECISION
4.2	Thioglycolic acid and Thiolactic acid combinations	Adopted Indonesia’s proposal of a revised text after refinement: <i>“For general use of hair waving or straightening products the maximum concentration for combination of Thioglycolic acid and Thiolactic acid must not exceed 8% calculated as Thioglycolic Acid.”</i>	<ul style="list-style-type: none"> • ACSB Secretary to include this text into Annex III, Refs 2a and A9, to replace the corresponding current text. • ACSB Secretary to check the history of entry in Annex III, Ref A7 which permits the use of Thioacids and their derivatives for all products with the condition <i>“not for use around the eye area”</i>, it contradicts refs 2a and A9. • ACA is tasked to draft a separate document clarifying the calculation of the 8% maximum level calculated as Thioglycolic acid

28TH ACSB MEETING SUMMARY REPORT

4.3	Triclosan	Listing of Triclosan in ACD Annexes <i>To clarify the listing of Triclosan in ACD Annexes VI and III, and also the treatment of multifunctional ingredients</i>	<ul style="list-style-type: none">• To defer further discussion to the 29th ACSB Meeting• No response from EC due to their current very heavy workload• No change to the ACD Annex listing of Triclosan, while awaiting further written confirmation from the European Commission on whether Triclosan in cosmetic products is permitted for purposes other than preserving the product
-----	-----------	--	--

CONFIDENTIAL

28TH ACSB MEETING SUMMARY REPORT

4.4	EU 2013/344	<p>Remaining Ingredients, EU Annex III Ref #103-205 that had not yet received ACSB Decision</p> <ul style="list-style-type: none">• EU Ref #103-184 and 196 are commonly used fragrance ingredients, controlled by IFRA Standards• Remaining ingredients are already included in ACD Annex II or Annex III	<ul style="list-style-type: none">• No changes to any Annex as in ASEAN it is mandatory to have IFRA compliance• Ref#103-184 will be marked “<i>intentionally left blank</i>” in Annex III• Ref#196 Verbena Essential Oil is already listed in Annex II Ref# 450• In the EU during implementation, there was no labeling implication and test methods were part of in-market control that fell within the remit of local competent authorities
-----	-------------	---	---

28TH ACSB MEETING SUMMARY REPORT

4.5	EU 2017/237	<p>Hair dyes added to EU Annex III</p> <ul style="list-style-type: none"> • N,N'-Bis(2-hydroxyethyl)-2-Nitro-p-phenylenediamine, 2,6-Dihydroxyethyl-aminotoluene, HC Red No. 17, HC Yellow No. 17, 1-Hexyl-4,5-diaminopyrazole sulphate, 2,5,6-Triamino-4-pyrimidinol sulphate, Hydroxyethoxyaminopyrazolopyridine HCl, 3-Amino-2,6-dimethylphenol, Basic Brown 17 and Basic Blue 124 	<ul style="list-style-type: none"> • ACSB to include the new entries to Annex III • Grace Period: Effective 1st Dec 2019 only compliant products can be placed in the market, and non-compliant products must be completely withdrawn from the market • ACA to share any usage data on these materials and member states to share any PMS data at the 29th ACSB Meeting
4.6	Lyril (HICC)	Indonesia's adoption of the same implementation date as other member states	Effective 23 rd August 2021, no cosmetic products with the banned materials can be placed in all ASEAN markets and non-compliant products must be completely withdrawn from the market

28TH ACSB MEETING SUMMARY REPORT

4.7	EU 2017/1413	Zinc oxide in products that may lead to lung exposure by inhalation	<ul style="list-style-type: none"> • No change to the text adopted previously into ACD Annexes “<i>not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation</i>” • ACA to support ASEAN SMEs with the required risk assessment as part of ACA Safety Assessment workshops
4.8	Climbazole	Continued discussion of the proposed Annex III listing	<ul style="list-style-type: none"> • Agreed to ACA’s proposal to maintain the current Annex listing for Climbazole in Annex VI with a (+) until the EU regulation has been published • ACA will review the developments in EU on Climbazole and present during the 29th ACSB Meeting • Member states to gather information detailing products available in their markets and provide ACA on a timely manner so that ACA can consider the exposure scenarios before the 29th ACSB Meeting

28TH ACSB MEETING SUMMARY REPORT

4.9	N-Methylpyrrolidone (NMP)	Reviewing the safety profile of NMP and discussion of the possible restriction of NMP	To consider NMP further following any developments in EU
4.10	Alpha Arbutin, Beta Arbutin and Deoxyarbutin	<ul style="list-style-type: none"> • Reviewing the safety profile of arbutins detailing the acceptable MoS for alpha, beta-arbutin • SCCS's conclusion that deoxyarbutin might not be considered safe in cosmetics 	To wait for final EU decision, expected around June 2018 and to discuss further at the 29 th ACSB Meeting
4.11	Ethyl Tosylamide	Indonesia's proposal for a new text for Annex II, Ref# 307, to clarify the scope of that reference	ACSB Secretary to amend Annex II, Ref# 307 to replace with the proposed text <i>"Sulphanilamide and its derivatives obtained by substitution of one or more H-atoms of the -NH2 groups, and their salts"</i>
4.12	Potassium Alum	Indonesia's concern on use in feminine hygiene products with extended contact times with mucous membranes which may lead to very severe irritation	To have a warning label to manage this issue
4.13	1,4 Dioxane	Trace levels of 1,4 Dioxane	ACA to draft a statement detailing a maximum 25 ppm of 1,4-dioxane as initial formal guideline that will be added into the ASEAN Guideline for Limits of Contaminants for Cosmetics

28TH ACSB MEETING SUMMARY REPORT

5	New issuance of EU Regulations	EU 2017/2228 Peanut Oil and Hydrolyzed Wheat Protein <ul style="list-style-type: none">• Proposal to restrict the permitted composition	<ul style="list-style-type: none">• Indonesia intends to report on the incidences of allergy to peanut oil and to hydrolyzed wheat protein reported during the 29th ACSB Meeting• ACSB Secretary to amend Annex III to include new entries for peanut oil and hydrolyzed wheat protein following the corresponding entries in EU2017/2228.• Effective 1st Dec 2019 only compliant products can be placed in the market, and non-compliant products must be completely withdrawn from the market, except Indonesia which is still reviewing this matter
---	--------------------------------	---	---

28TH ACSB MEETING SUMMARY REPORT

6.1	Malachite Green	<p>Philippines's proposal to clarify the scope of substances to be covered by Annex II, Ref# 1188 and whether additional CAS numbers referring to Malachite Green compounds should also be included</p> <ul style="list-style-type: none"> • CAS 633-03-4 is already listed in Annex II Ref #1299 	<ul style="list-style-type: none"> • ACA to review the safety information for the remaining 2 substances and present the findings at the 29th ACSB Meeting <ul style="list-style-type: none"> ○ CAS 2437-29-8 ○ CAS 61725-50-6 • Further discussion on products notifications containing Malachite Green during the 29th ACSB Meeting
6.2	Annex VI Clarifications and Corrections	<p>Thailand's proposal to amend the preamble text to Annex VI due to the insufficient clarity on the permitted use of Annex VI listed preservative substances for other purposes</p>	<ul style="list-style-type: none"> • ACA to review the ongoing process in EU and update on information received during the 29th ACSB Meeting • Member States will review the proposal from Thailand for further discussion during the 29th ACSB Meeting

28TH ACSB MEETING SUMMARY REPORT

9	Joint Opinion Statements	<ul style="list-style-type: none"> • ACA’s revised proposed process for Joint Opinion Statements • Philippines proposal of 3 ingredients of concerns as suitable substances for Joint Opinion Statements: Heavy Metals, Hydroquinone and Tretinoin 	<ul style="list-style-type: none"> • ACA’s proposal adopted as the approved process for writing and approving Joint Opinion Statements • Each AMS to propose 5 ingredients of concern to ACSB Secretary in good time • ACA to consolidate and form Task Forces with AMS and commence work to write Joint Opinion Statements for priority ingredients
8	Process for New Materials	<p>ACA’s proposal of a revised process for introduction and review of new materials into ACD Annexes IV, VI and VII that did not arise from new EU regulations</p> <ul style="list-style-type: none"> • Indonesia proposed a modification that clarified that if the proposal came via National Association then the National Regulatory Agency would be kept cognizant of the proposal. • The Meeting agreed that the documents governing the new material process could become an ASEAN guideline document after AMS review and subsequent ACC endorsement 	<p>ACA to present the revised process in the 29th ACSB Meeting</p>

28TH ACSB MEETING SUMMARY REPORT

9	Other Matters: Indonesia's proposal to establish an ASEAN Fragrance Association assisted by IFRA	IFRA has already established a legal entity registered in Singapore and IFRA was also represented within ACA	
9	Other Matters: Singapore's proposal to discuss the need to assess the safety of residual antimony in cosmetic products	ACA proposed that a guideline should not be set for antimony and to keep the meeting informed of the developments in the issue	ACA to review the safety of Antimony and bring it to the 29 th ACSB Meeting A Joint Opinion Statement on antimony could be prepared

CONFIDENTIAL